In treating opioid use disorder, which statement about buprenorphine is true?

In treating opioid use disorder, which statement about buprenorphine is true?

• A. It can be started only when the patient is in withdrawal; pregnant patients can receive buprenorphine only; most others get buprenorphine/naloxone; formulations include tablet and sublingual; no longer require an X-waiver
• B. It can be started at any time without withdrawal and does not involve naloxone
• C. It is available only as an injectable formulation
• D. Prescribers always need an X-waiver to initiate treatment

Answer: (A)

Buprenorphine is a partial opioid agonist used to treat opioid use disorder because it can suppress withdrawal and cravings while having a ceiling effect that lowers overdose risk. Induction typically occurs when the patient is in withdrawal to avoid precipitated withdrawal: buprenorphine binds strongly to opioid receptors and can displace other opioids, so starting it too soon after a full agonist can suddenly worsen withdrawal symptoms. This is why initiation is usually timed with evident withdrawal rather than right after use of other opioids. In pregnancy, buprenorphine is a preferred option and is used safely; it is not the only choice, but it is commonly chosen due to fetal and neonatal outcomes. The standard outpatient approach often uses a buprenorphine formulation combined with naloxone to deter misuse; most patients can start on this combination, though monotherapy with buprenorphine alone is possible in some situations. Available formulations include sublingual tablets and films, which are convenient for induction and ongoing treatment. Regarding access, prescribers historically needed an X-waiver to treat opioid use disorder with buprenorphine. There have been regulatory moves aiming to remove or relax this requirement to broaden access, but the specifics can vary by jurisdiction and over time, so it’s important to stay updated with current local rules.

Buprenorphine is a partial opioid agonist used to treat opioid use disorder because it can suppress withdrawal and cravings while having a ceiling effect that lowers overdose risk. Induction typically occurs when the patient is in withdrawal to avoid precipitated withdrawal: buprenorphine binds strongly to opioid receptors and can displace other opioids, so starting it too soon after a full agonist can suddenly worsen withdrawal symptoms. This is why initiation is usually timed with evident withdrawal rather than right after use of other opioids.

In pregnancy, buprenorphine is a preferred option and is used safely; it is not the only choice, but it is commonly chosen due to fetal and neonatal outcomes. The standard outpatient approach often uses a buprenorphine formulation combined with naloxone to deter misuse; most patients can start on this combination, though monotherapy with buprenorphine alone is possible in some situations. Available formulations include sublingual tablets and films, which are convenient for induction and ongoing treatment.

Regarding access, prescribers historically needed an X-waiver to treat opioid use disorder with buprenorphine. There have been regulatory moves aiming to remove or relax this requirement to broaden access, but the specifics can vary by jurisdiction and over time, so it’s important to stay updated with current local rules.